Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Pharvaris to $35 from $32 and keeps an Overweight rating on the shares after the company reported that deucrictibant for the preventive treatment of hereditary angioedema, or HAE, met the primary endpoint in Phase 2 CHAPTER-1 trial. The data “represent another derisking event” for deucrictibant and “further position it as a viable potential therapy for both the on-demand and prophylactic treatment of HAE,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PHVS:
- Pharvaris 11.125M share Secondary priced at $24.00
- Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
- Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
- Pharvaris announces ‘positive’ data from CHAPTER-1 study of deucrictibant
- Pharvaris to Present at the GA²LEN UCARE Conference 2023
Questions or Comments about the article? Write to editor@tipranks.com